Candidate Pipeline

Boulder BioScience has developed two hospital-dispensed, critical care drug candidates for treatment of Traumatic Brain Injury (TBI) including Concussion and Acute Ischemic Stroke (AIS).

The  lead drug candidate, BR9001, provides a first-in-class small molecule for oral administration as an ER and in-field formulation for TBI and concussions.  Projected use includes pre-hospital administration in screened  TBI and AIS patients. BR4044 is an intravenous injection formulation designed for administration by emergency professionals following TBI. BR4044 is also designed for use by  interventional neuro-radiologists as an adjunct before and during Thrombectomy for AIS.

Candidate
Route of Administration
Indication
Early Preclinical
Late Preclinical
Phase 1
BR 9001
Oral
Acute Ischemic Stroke (AIS)
*1
BR 4044
Intravenous
Severe Traumatic Brain Injury
*2
BR 9001
Oral
Mild TBI Concussion
BR 4044
Intravenous
Mod-Severe TBI Contusion
BR 4044
Intravenous
Acute AIS Undergoing Thrombectomy
1

BR9001 – Oral, Self-Micro-Emulsifying BR9001 is IND-enabled with a completed 28 day GLP Safety Toxicology PK study in rats completed.

2

BR4044 – Intravenous nano-suspension BR4044 has completed a pivotal efficacy study treating TBI with brain contusion in rats.

Skip to content